Objectives And Design: Using sequences obtained for routine resistance testing, we characterised the molecular patterns of HIV-1 transmission and factors associated with being part of a transmission cluster among individuals who in 2008-2014 presented with primary HIV-1 infection (PHI) at 11 urban centres across Italy.
Methods: sequences were obtained by Sanger sequencing. Transmission clusters were identified by phylogenetic analysis (maximum likelihood method, confirmed by Bayesian analysis). Multivariable logistic regression explored factors associated with a participant being part of a transmission cluster.
Results: The PHI cohort comprised 186 participants (159/186, 85.5% males) with median age 44 years, median CD4 count 464 cells/mm and median plasma HIV-1 RNA 5.6 log copies/mL. Drug resistance associated mutations were found in 16/186 (8.6%). A diversity of non-B subtypes accounted for 60/186 (32.3%) of all infections. A total of 17 transmission clusters were identified, including 44/186 (23.7%) participants. Each cluster comprised 2-6 sequences. Non-B subtypes accounted for seven clusters and 22/44 (50%) of clustered sequences. In multivariable logistic regression analysis, factors associated with being part of a transmission cluster comprised harbouring a non-B subtype (adjusted OR (adjOR) 2.28; 95% CI 1.03 to 5.05; p=0.04) and showing a lower plasma HIV-1 RNA (adjOR 0.80, 95% CI 0.64 to 0.99; p=0.04).
Conclusions: There was a large contribution of diverse non-B subtypes to transmission clusters among people presenting with acute or recent HIV-1 infection in this cohort, illustrating the evolving dynamics of the HIV-1 epidemic in Italy, where subtype B previously dominated.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/sextrans-2021-055289 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Next-generation sequencing and drug resistance mutations of HIV-1 subtypes in people living with HIV in Sicily, Italy, 2021-2023.
J Glob Antimicrob Resist
December 2024
Department of Health Promotion, Mother and Child Care, Internal Medicine, and Medical Specialties "G D'Alessandro, " University of Palermo, Palermo, Italy; Microbiology and Virology Unit, AOU Policlinico "P. Giaccone", 90127 Palermo, Italy.
Objectives: HIV-1 infection continues to be a significant public health concern, notwithstanding the expanded utilization of antiretroviral treatment (ART), due to the emergence of drug resistance. The prevalence of transmitted drug resistance remains uncertain, particularly concerning integrase inhibitors. This study aimed to assess the extent of HIV resistance in both ART-naïve and experienced individuals living with HIV (PLHIV) at the University Hospital in Palermo, Italy.
View Article and Find Full Text PDFInitial HIV-1 viral load in French Guiana: Factors associated with viral load set point differences.
IJID Reg
December 2024
COREVIH Guyane, Centre hospitalier de Cayenne, Cayenne, French Guiana.
Objectives: HIV viral load set points may vary between virus subtypes and host characteristics. The HIV epidemic in French Guiana entails a mix of viruses and populations of cosmopolitan origins. In this epidemiological context, we aimed to determine whether, at the scale of our territory, we could identify differences in HIV-1 viral load setpoints in our hospital cohort.
View Article and Find Full Text PDFComparison of the Performance of Commercially Available Quantitative Viral Load Assays Using Clinical Samples from Patients from Regions Where Distinct HIV-1 Subtypes Co-Circulate: Potential Implications for Patient Management.
AIDS Res Hum Retroviruses
October 2024
Infectious Diseases Division, Paulista School of Medicine, Federal University of São Paulo, São Paulo, Brazil.
HIV RNA plasma viral load (VL) is the standard surrogate marker to monitor response to antiretroviral treatment (ART). We compared the linearity, repeatability, and concordance of six commercially available HIV RNA VL platforms using clinical samples from patients from Brazilian sites where different HIV-1 subtypes co-circulate. A total of 150 plasma samples from each city were collected in Curitiba, Southern Brazil (subtype C), São Paulo (subtype B), and Santos (BF recombinants), Southeast Brazil.
View Article and Find Full Text PDFK103N, V106M and Y188L Significantly Reduce HIV-1 Subtype C Phenotypic Susceptibility to Doravirine.
Viruses
September 2024
HIV Pathogenesis Research Unit, University of the Witwatersrand, Johannesburg 2193, South Africa.
Article Synopsis
- Doravirine (DOR) is a new HIV treatment that works against some drug-resistant strains, but its effectiveness against non-B subtypes like HIV-1 subtype C is not fully understood.
- The study used South African data to examine how certain known mutations associated with resistance affect DOR susceptibility, finding that mutations such as V106M and Y188L significantly reduce DOR effectiveness.
- The research emphasizes the importance of genotypic drug resistance testing before starting DOR-based therapy, especially in patients with a history of efavirenz or nevirapine treatment failures.*
Comparison of Different HIV-1 Resistance Interpretation Tools for Next-Generation Sequencing in Italy.
Viruses
September 2024
Department of Experimental Medicine, University of Rome "Tor Vergata", 00133 Rome, Italy.
Article Synopsis
- Next-generation sequencing (NGS) is replacing Sanger sequencing for HIV genotypic drug resistance testing, and this study assessed how consistent different interpretation tools are in a real-world setting.
- The research involved analyzing NGS results from 11 Italian labs using the AD4SEQ HIV-1 Solution v2 kit and compared interpretations from SmartVir, HyDRA Web, and Stanford HIVdb.
- Findings indicated that viremia levels and HIV subtypes influence the validity of NGS-GRT, with only mutations present at frequencies over 10% showing reliable agreement among the interpretation tools.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!